Improvements in the metabolic milieu following Roux-en-Y gastric bypass and the arrest of diabetic kidney disease

Experimental Physiology

Volumn 99, Issue 9, 2014, Pages 1146-1153

  Docherty, Neil G ^a   le Roux, Carel W ^a,b,c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE CONTROL; HUMAN; HYPERTENSION; KIDNEY DISEASE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROUX Y ANASTOMOSIS; STOMACH BYPASS; ANIMAL; BLOOD; BLOOD PRESSURE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE COURSE; ENTEROENDOCRINE CELL; GLUCOSE BLOOD LEVEL; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; REMISSION; RISK FACTOR; SIGNAL TRANSDUCTION; TIME; TREATMENT OUTCOME; WEIGHT REDUCTION;

BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; LIPID;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; ENTEROENDOCRINE CELLS; GASTRIC BYPASS; HUMANS; KIDNEY; LIPIDS; OBESITY; REMISSION INDUCTION; RISK FACTORS; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84908304137     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2014.078790     Document Type: Article

References (45)

1. Abdullah A, Peeters A, de Courten M & Stoelwinder J (2010). The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract 89, 309-319.
2. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J & de Boer IH (2013). Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24, 302-308.
3. Alam ML, Van der Schueren BJ, Ahren B, Wang GC, Swerdlow NJ, Arias S, Bose M, Gorroochurn P, Teixeira J, McGinty J & Laferrère B (2011). Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes. Diabetes Obes Metab 13, 378-381.
4. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K & Schoelles K (2004). Bariatric surgery: a systematic review and meta-analysis. JAMA 292, 1724-1737.
5. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP & Sledge I (2009). Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122, 248-256.e245.
6. Bueter M, Ashrafian H, Frankel AH, Tam FW, Unwin RJ & le Roux CW (2011). Sodium and water handling after gastric bypass surgery in a rat model. Surg Obes Relat Dis 7, 68-73.
7. Bueter M, Dubb SS, Gill A, Joannou L, Ahmed A, Frankel AH, Tam FW & le Roux CW (2010). Renal cytokines improve early after bariatric surgery. Br J Surg 97, 1838-1844.
8. Carlsson LM, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, Jacobson P, Lönroth H, Maglio C, Näslund I, Pirazzi C, Romeo S, Sjöholm K, Sjöström E, Wedel H, Svensson PA & Sjöström L (2012). Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 367, 695-704.
9. Castagneto M & Mingrone G (2012). The effect of gastrointestinal surgery on insulin resistance and insulin secretion. Curr Atheroscler Rep 14, 624-630.
10. National Centre for Health & Care Excellence (2006). Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. http://www.nice.org.uk/guidance/CG43/chapter/introduction (last accessed August 1st 2014).
11. Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, Horlick M, Kalarchian MA, King WC, Mitchell JE, Patterson EJ, Pender JR, Pomp A, Pories WJ, Thirlby RC, Yanovski SZ & Wolfe BM; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium (2013). Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA 310, 2416-2425.
12. Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BP, Lessa LM, Malnic G & Girardi AC (2011). Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 301, F355-F363.
13. de Jonge C, Rensen SS, Verdam FJ, Vincent RP, Bloom SR, Buurman WA, le Roux CW, Schaper NC, Bouvy ND & Greve JW (2013). Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg 23, 1354-1360.
14. Dirksen C, Jørgensen NB, Bojsen-Møller KN, Jacobsen SH, Hansen DL, Worm D, Holst JJ & Madsbad S (2012). Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 55, 1890-1901.
15. Dixon JB, Zimmet P, Alberti KG & Rubino F; International Diabetes Federation Taskforce on Epidemiology and Prevention (2011). Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med 28, 628-642.
16. Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, Hosoba M, Tsukiyama K, Narita T, Takahashi T, Drucker DJ, Seino Y & Yamada Y (2014). The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 85, 579-589.
17. Gutzwiller JP, Hruz P, Huber AR, Hamel C, Zehnder C, Drewe J, Gutmann H, Stanga Z, Vogel D & Beglinger C (2006). Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 73, 142-150.
18. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B & Beglinger C (2004). Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89, 3055-3061.
19. Hallersund P, Sjöström L, Olbers T, Lönroth H, Jacobson P, Wallenius V, Näslund I, Carlsson LM & Fändriks L (2012). Gastric bypass surgery is followed by lowered blood pressure and increased diuresis - long term results from the Swedish Obese Subjects (SOS) study. PLoS One 7, e49696.
20. Heneghan HM, Cetin D, Navaneethan SD, Orzech N, Brethauer SA & Schauer PR (2013). Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surg Obes Relat Dis 9, 7-14.
21. Hinojosa MW, Varela JE, Smith BR, Che F & Nguyen NT (2009). Resolution of systemic hypertension after laparoscopic gastric bypass. J Gastrointest Surg 13, 793-797.
22. Iaconelli A, Panunzi S, De Gaetano A, Manco M, Guidone C, Leccesi L, Gniuli D, Nanni G, Castagneto M, Ghirlanda G & Mingrone G (2011). Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up. Diabetes Care 34, 561-567.
23. Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG, Swain JM, Laqua P, Jensen MD & Bantle JP (2013). Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 309, 2240-2249.
24. Jiménez A, Casamitjana R, Flores L, Delgado S, Lacy A & Vidal J (2013). GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects. Ann Surg 257, 894-899.
25. Kaji I, Karaki S & Kuwahara A (2014). Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release. Digestion 89, 31-36.
26. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA & Drucker DJ (2013). GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19, 567-575.
27. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG & Bloom SR (2006). Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243, 108-114.
28. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G & Rubino F (2012). Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366, 1577-1585.
29. Miras AD, Chuah LL, Lascaratos G, Faruq S, Mohite AA, Shah PR, Gill M, Jackson SN, Johnston DG, Olbers T & le Roux CW (2012). Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes. Diabetes Care 35, e81.
30. Miras AD & le Roux CW (2013). Mechanisms underlying weight loss after bariatric surgery. Nat Rev Gastroenterol Hepatol 10, 575-584.
31. Moreno C, Mistry M & Roman RJ (2002). Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 434, 163-167.
32. Navarro-Díaz M, Serra A, Romero R, Bonet J, Bayés B, Homs M, Pérez N & Bonal J (2006). Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol 17, S213-S217.
33. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM & Dohm L (1995). Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222, 339-350; discussion 350-332.
34. Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, Drucker DJ & Vallon V (2012). Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol 303, F963-F971.
35. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE & Kashyap SR; STAMPEDE Investigators (2014). Bariatric surgery versus intensive medical therapy for diabetes - 3-year outcomes. N Engl J Med 370, 2002-2013.
36. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE & Bhatt DL (2012). Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366, 1567-1576.
37. Schlatter P, Beglinger C, Drewe J & Gutmann H (2007). Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 141, 120-128.
38. Shah M, Law JH, Micheletto F, Sathananthan M, Dalla Man C, Cobelli C, Rizza RA, Camilleri M, Zinsmeister AR & Vella A (2014). Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes 63, 483-493.
39. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M & Wedel H; Swedish Obese Subjects Study Scientific Group (2004). Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351, 2683-2693.
40. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G & Carlsson LM; Swedish Obese Subjects Study (2007). Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357, 741-752.
41. Sorensen C, Jensen E, Poulsen S, Holst J & Holstein-Rathlou NH (2014). Direct effect of glucagon-like peptide-1 on the autoregulatory response of the afferent arteriole. FASEB vol. 28 no. 1 Supplement 69.2
42. Tee MC, Cao Y, Warnock GL, Hu FB & Chavarro JE (2013). Effect of bariatric surgery on oncologic outcomes: a systematic review and meta-analysis. Surg Endosc 27, 4449-4456.
43. Thomson SC, Kashkouli A & Singh P (2013). Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am J Physiol Renal Physiol 304, F137-F144.
44. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ & Couture P (2011). Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 13, 366-373.
45. Welsh GI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, Lennon R, Pons DA, Owen RJ, Satchell SC, Miles MJ, Caunt CJ, McArdle CA, Pavenstädt H, Tavaré JM, Herzenberg AM, Kahn CR, Mathieson PW, Quaggin SE, Saleem MA & Coward RJ (2010). Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 12, 329-340.